A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer

European Journal of Cancer

Volumn 43, Issue 7, 2007, Pages 1153-1160

  Villman, Kenneth ^a   Öhd, John F ^b   Lidbrink, Elisabet ^b   Malmberg, Lena ^c   Lindh, Birgitta ^d   Blomqvist, Carl ^e   Nordgren, Hans ^e   Bergh, Jonas ^b   Bergström, Daniel ^f   Ahlgren, Johan ^g,h  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b Karolinska Krankenhaus   (Sweden)

^c CENTRAL HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f Roche AB   (Sweden)

^g Gävleborg County Hospital   (Sweden)

^h Centre of Clinical Research   (Sweden)

Author keywords

Biomarker; Breast cancer; Capecitabine; Cisplatin; Clinical trial; Epirubicin; Neoadjuvant; Pathologic complete response; Phase II

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIXYRAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METOCLOPRAMIDE; PACLITAXEL; PLATINUM DERIVATIVE; SEROTONIN 3 ANTAGONIST; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERCOAGULABILITY; INFECTION; LEUKOPENIA; MASTECTOMY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; ONCOGENE NEU; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SPLEEN INFARCTION; STOMATITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MASTECTOMY, RADICAL; MIDDLE AGED; NEOADJUVANT THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34247262143     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.02.002     Document Type: Article

References (32)

1. Mauri D., Pavlidis N., and Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97 (2005) 188-194
2. Karlsson Y.A., Malmstrom P.O., Hatschek T., et al. Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide: prognostic and therapeutic implications. Cancer 83 (1998) 936-947
3. Baldini E., Gardin G., Giannessi P.G., et al. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol 14 (2003) 227-232
4. Therasse P., Mauriac L., Welnicka-Jaskiewicz M., et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 21 (2003) 843-850
5. Evans T.R., Yellowlees A., Foster E., et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol 23 (2005) 2988-2995
6. Bear H.D., Anderson S., Smith R.E., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24 (2006) 2019-2027
7. Smith I.C., Heys S.D., Hutcheon A.W., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20 (2002) 1456-1466
8. Hutcheon A.W., Heys S.D., and Sarkar T.K. Aberdeen Breast Group. Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat 79 Suppl 1 (2003) S19-S24
9. Blum J.L., Jones S.E., Buzdar A.U., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17 (1999) 485-493
10. O'Shaughnessy J.A., Blum J., Moiseyenko V., et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12 (2001) 1247-1254
11. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20 (2002) 2812-2823
12. Beslija S., Obralić N., Basic H., et al. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). J Clin Oncol ASCO Annual Meeting Proceedings 24 18S (2006) 571
13. Smith I.E., A'Hern R.P., Coombes G.A., et al. ; TOPIC Trial Group. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 15 (2004) 751-758
14. Evans T.R., Pentheroudakis G., Paul J., et al. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Ann Oncol 13 (2002) 1469-1478
15. Mano MS, Rosa DD, De Azambuja E, Ismael GF, Durbecq V. The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. Cancer Treat Rev. 2006 Nov 16; [Epub ahead of print].
16. Miwa M., Ura M., Nishida M., et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34 (1998) 1274-1281
17. Salonga D., Danenberg K.D., Johnson M., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6 (2000) 1322-1327
18. Thall P.F., and Simon R. Practical Bayesian guidelines for phase IIB clinical trials. Biometrics 50 (1994) 337-349
19. Bonnefoi H., Diebold-Berger S., Therasse P., et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?. Ann Oncol 14 (2003) 406-413
20. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 (1998) 2672-2685
21. Anderson W.F., Chu K.C., and Chang S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?. J Clin Oncol 21 (2003) 2254-2259
22. Chang J.C., Wooten E.C., Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 (2003) 362-369
23. Gianni L., Zambetti M., Clark K., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23 (2005) 7265-7277
24. Cho E.K., Lee W.K., Im S.A., et al. A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer. Oncology 68 (2005) 333-340
25. Cunningham D., Rao S., Starling N., et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial. J Clin Oncol ASCO Annual Meeting Proceedings Part I 24 18S (2006) LBA4017
26. Park S.H., Park Y.H., Lee J.N., et al. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer 106 (2006) 361-365
27. Doherty K.M. Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs 3 (1999) 113-119
28. Kris M.G., Hesketh P.J., Somerfield M.R., et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. J Clin Oncol 24 (2006) 2932-2947
29. Van Cutsem E., Hoff P.M., Blum J.L., Abt M., and Osterwalder B. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 13 (2002) 484-485
30. Kuzel T., Esparaz B., Green D., and Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 65 (1990) 885-889
31. Licciardello J.T., Moake J.L., Rudy C.K., Karp D.D., and Hong W.K. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 42 (1985) 296-300
32. Bertomeu M.C., Gallo S., Lauri D., Levine M.N., Orr F.W., and Buchanan M.R. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis 8 (1990) 511-518